Mignon L. Loh

Dec 7, 2023 | nature.com | Meenakshi Devidas |Mignon L. Loh |Naomi J. Winick |Stephen P. Hunger |William Carroll

AbstractOsteonecrosis is a significant toxicity of acute lymphoblastic leukemia (ALL) therapy. In retrospective analyses, superior event-free survival was noted among affected adolescents in an earlier trial. We prospectively assessed osteonecrosis incidence, characteristics, and risk factors in patients 1–30 years with newly diagnosed high-risk B-ALL on COG AALL0232.